|
Website:
http://www.immunogen.com
Phone: +1 617 995-2500 |
Address:
128 Sidney Street
Cambridge, MASSACHUSETTS 02139 |
Company Description
ImmunoGen, Inc.. The Group's principal activity is to develop and produce commercial anti-body based cancer therapeutics and other pharmaceuticals based on molecular immunology. A preclinical testing of a second tumor-activated prodrugs candidate, huN901-DM1 is conducted for the treatment of small-cell lung cancer. The product candidates of the Group are tumor-activated prodrugs or TAPs which are based on proprietary technology platform that combines monoclonal antibodies that targets tumor cells and potent drugs. Develops and produces commercial anti-body based cancer therapeutics and other pharmaceuticals based on molecular immunology
Key People
| Chairman, President & Chief Executive | Dr. Mitchel Sayare |
| Executive Vice President, Chief Financial Officer & Treasurer | Daniel M. Junius |
| Secretary | Jonathan L. Kravetz |
Related Business Topics
0-9 |
A |
B |
C |
D |
E |
F |
G |
H |
I |
J |
K |
L |
M |
N |
O |
P |
Q |
R |
S |
T |
U |
V |
W |
X |
Y |
Z
I
Breaking News
Reuters - Nov. 19, 2009, 2:59 PM
Forbes.com - Nov. 19, 2009, 2:47 PM
Reuters - Nov. 17, 2009, 10:24 AM
CNBC - Nov. 17, 2009, 9:44 AM
Forbes.com - Oct. 27, 2009, 4:06 AM
More Immunogen News
